NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

CompletedN/A

Sponsor: Takeda

Conditions: Crohn's Disease

Interventions: Vedolizumab (Genetical Recombination)

Countries: Japan

The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Have moderate or severe active CD
2. Have inadequate response to existing therapies

Exclusion Criteria:

Patients with any contraindication for vedolizumab

Locations (1)

Tokyo, Japan